Esperion Therapeutics, Inc. (NASDAQ:ESPR) Receives Average Recommendation of “Hold” from Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) have earned a consensus recommendation of “Hold” from the four ratings firms that are covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $8.83.

ESPR has been the subject of several recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $16.00 target price on shares of Esperion Therapeutics in a research note on Friday, June 28th. StockNews.com cut shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 17th. Bank of America lowered shares of Esperion Therapeutics from a “neutral” rating to an “underperform” rating and decreased their price target for the company from $2.90 to $2.50 in a report on Thursday, June 20th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $8.00 price target on shares of Esperion Therapeutics in a report on Friday, June 28th.

Esperion Therapeutics Trading Down 5.5 %

Shares of Esperion Therapeutics stock opened at $2.06 on Monday. Esperion Therapeutics has a 12-month low of $0.70 and a 12-month high of $3.40. The stock has a market cap of $390.29 million, a PE ratio of -2.08 and a beta of 1.02. The company has a 50-day moving average of $2.43 and a two-hundred day moving average of $2.37.

Esperion Therapeutics (NASDAQ:ESPR) last issued its quarterly earnings data on Tuesday, May 7th. The biopharmaceutical company reported $0.34 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.42. The business had revenue of $137.74 million for the quarter, compared to analysts’ expectations of $53.11 million. On average, sell-side analysts forecast that Esperion Therapeutics will post -0.01 EPS for the current fiscal year.

Hedge Funds Weigh In On Esperion Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Capital Advisors Wealth Management LLC lifted its holdings in shares of Esperion Therapeutics by 22.9% during the 2nd quarter. Capital Advisors Wealth Management LLC now owns 26,800 shares of the biopharmaceutical company’s stock valued at $59,000 after acquiring an additional 5,000 shares in the last quarter. Summit Financial LLC lifted its holdings in shares of Esperion Therapeutics by 26.4% during the 2nd quarter. Summit Financial LLC now owns 32,687 shares of the biopharmaceutical company’s stock valued at $73,000 after acquiring an additional 6,823 shares in the last quarter. Spire Wealth Management lifted its holdings in shares of Esperion Therapeutics by 69.2% during the 4th quarter. Spire Wealth Management now owns 17,767 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 7,267 shares in the last quarter. Private Portfolio Partners LLC acquired a new position in Esperion Therapeutics in the 4th quarter worth $30,000. Finally, National Bank of Canada FI boosted its position in Esperion Therapeutics by 115.9% in the 2nd quarter. National Bank of Canada FI now owns 19,050 shares of the biopharmaceutical company’s stock valued at $44,000 after buying an additional 10,225 shares during the last quarter. Institutional investors and hedge funds own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.